5229
Omnia Mohamed Abdel-Aziz Hassan
Evaluation of Avian Influenza H5N1 Plasmid-Based Inactivated Egyptian Vaccine and Treatment with Antiviral Drugs
uaccine, Influenza,Inactivated
Although several essential preventive and therapeutic strategies could help to combat severe IAV pandemics and epidemics, vaccination is still the primary defence line to combat IAV infection (Houser & Subbarao, 2015). Therefore, this work was designed to study the potency of plasmid-based H5N1 inactivated vaccine in controlling H5N1virus infection; and the antigenic variation as well as the cross-reactivity of the currently applied imported avian influenza vaccines. Besides, we performed a deliberate screening for the antiviral activity of commercial FDA approved antiviral drugs (acyclovir, ribavirin, amantadine HCl and Oseltamivir) to control H5N1infection. Moreover, some commercial disinfectants (Chlorine; 40.5 g/L and chloroxylenol4.8 W/V) were further investigated for their anti-septic activity in controlling avian influenza infection (H5N1). Herein, to determine the level of maternal antibodies (MA), 10 blood samples were collected randomly from 400 broiler chickens at days 1, 7, 10 and 14. Subsequently, sera were extracted and examined for their MA titer. After 2 weeks and waning of MA, experimental chickens were divided into 8 groups. Each group has received 0.5 ml of CEVAC vaccine intramuscular (IM),Re- 5strainAI vaccine, ME FLUVAC vaccine, AI-VAC H5 vaccine, Kemiflu vak AI KV vaccine, and Re-1 strain AI vaccine, groupwas left as blank control, rg (M2583D)AI vaccine, respectively. The levels of raised antibodies in the sera of the vaccinated chicken were monitored with the hemagglutination inhibition assays using rg A/Duck/Egypt/M2383A/2010(H5N1, E3, rM2583A) as antigen. Except for the laboratory made rg (M2583D) group (8), the other vaccines preparations did not provide any detectable titers until day 35 including the commercial version of the laboratory-made rg (M2583A) vaccine (≥80 HIU). At day 42, Kemiflu Vac (Re-k) vaccine in group (5) showed a cross-reactive log titer of 80 HIU, whereas the other vaccines had log titers between 0.5 and 20 HIU as compared to the control group (log titer 30 HIU) During this trial, samples from cloacal and Oropharyngeal swabs were collected from day 14 to day 42 and tested by real time PCR for virus shedding. The inset of mortality throughout the experiment was relatively low (15%) and was not related to applied vaccines. Unexpectedly, we noticed a natural infection with H9-subtype in different treated and control groups.
2016
M.Sc
Cairo
Pharmacy